Skip to main content

Table 2 CMR, metabolic and clinical parameters before and after aortic valve replacement (AVR) and in healthy controls

From: Circulatory efficiency in patients with severe aortic valve stenosis before and after aortic valve replacement

Parameters Pre-AVR (n = 41) Post-AVR (n = 41) Healthy controls (n = 10) P value pre-AVR vs post-AVR P value pre-AVR vs healthy controls P values post-AVR vs healthy controls
CMR parameters
 Myocardial mass/BSA [mg/m2] 72 ± 21 50 ± 13 40 ± 8 < 0.001 < 0.001 0.019
 LVESD [mm] 34 ± 6 32 ± 4 34 ± 2 < 0.001 0.943 0.035
 Myocardial wall thickness end systolic [mm] 11 ± 2 10 ± 2 8 ± 1 < 0.001 < 0.001 0.001
 LVEDV/BSA [ml/m2] 93 ± 22 77 ± 13 82 ± 9 < 0.001 0.117 0.169
 LVESV/BSA [ml/m2] 41 ± 18 31 ± 9 34 ± 4 < 0.001 0.393 0.064
 LVEF [%] 58 ± 10 61 ± 7 59 ± 3 0.027 0.462 0.088
 LV mass-volume-index [g/ml] 0.8 ± 0.2 0.7 ± 0.2 0.5 ± 0.1 0.001 < 0.001 < 0.001
 RF [%] 9 ± 6 7 ± 5 3 ± 2 0.115 0.004 0.005
 Heart rate [bpm] 67 ± 11 70 ± 12 62 ± 10 0.189 0.302 0.104
 CO_total [l/min] 6.8 ± 1.9 6.3 ± 1.7 5.4 ± 1.2 0.048 0.041 0.184
 CI [(l/min)/m2] 3.5 ± 0.8 3.2 ± 0.7 2.9 ± 0.4 0.056 0.039 0.265
 SV_total [ml] 79 ± 20 76 ± 15 74 ± 19 0.396 0.440 0.440
 ECV midwall [%] 23 ± 2 27 ± 3   < 0.001 – –
 aECV midwall [ml] 32 ± 11 27 ± 9   < 0.001 – –
 aECV/BSA midwall [ml/m2] 16 ± 5 14 ± 4   < 0.001 – –
 GLS [%] − 21.2 ± 5 − 24.8 ± 4   < 0.001 – –
 Late gadolinium enhancement, n (%) 5 (16%) 8 (23%) – 1.000 – –
 Mitral regurgitation II-IV, n (%) 0 (0%) 1 (2%) 0 (0%) 1.000 – 0.618
Heart power parameters
 LV myocardial power [W/m2] 8 ± 3 5 ± 2 5 ± 0.8 < 0.001 < 0.001 0.924
 Circulatory power [W] 1.3 ± 0.4 1.3 ± 0.4 1.1 ± 0.3 0.462 0.097 0.462
 Circulatory efficiency [%] 9.3 ± 3 13.3 ± 5 12.3 ± 2 < 0.001 0.004 0.112
 Circulatory efficiency improvement [%] – 4.1 ± 5.7 – – – –
Metabolic parameters
 NT-pro-BNP [ng/l] 770 ± 926 334 ± 261 113 ± 113 < 0.001 < 0.001 0.001
 Hemoglobin [g/dl] 14.2 ± 1.3 13.5 ± 1.3 13.9 ± 0.8 0.011 0.607 0.184
 Hematocrit [%] 42 ± 4 42 ± 4 41 ± 3 0.609 0.511 0.497
Clinical parameters
 NYHA III-IV, n(%) 18 (35%) 3 (7%) 0 (0%) < 0.001 0.009 0.378
 Systolic blood pressure [mmHg] 137 ± 17 138 ± 19 136 ± 15 0.650 0.704 0.877
 Diastolic blood pressure [mmHg] 75 ± 10 75 ± 9 74 ± 9 0.872 0.868 0.831
 Mean arterial pressure [mmHg] 96 ± 11 96 ± 11 95 ± 9 0.948 0.803 0.822
 Mean aortic pressure gradient [mmHg] 56 ± 15 11 ± 5 5 ± 3 < 0.001 < 0.001 < 0.001
 Maximal aortic pressure gradient [mmHg] 83 ± 22 19 ± 7 9.5 ± 5 < 0.001 < 0.001 < 0.001
 Pulse pressure [mmHg] 63 ± 16 63 ± 16 62 ± 13 0.906 0.972 0.905
 6-min walk distance [m]   518 ± 84 538 ± 111 – – 0.646
  1. LVESD, left ventricular end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; RF, regurgitation fraction; HR, heart rate; CO, cardiac output; ECV, extracellular volume; aECV, absolute extracellular volume; GLS, global longitudinal strain; NT-pro-BNP, N terminales pro brain natriuretic peptide; NYHA, New York Heart Association
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us